Credit Suisse said the PCSK9 FDA panel discussion yesterday on Regeneron's (REGN) Praluent does not impact the firm's outlook for Esperion's ETC-1002 and the read through is limited. The firm expects Esperion's meeting with the FDA in July to be positive, given multiple Phase II studies that showed consistent LDL lowering as a monotherapy or in combination with ezetimibe and statins and the lifting of the FDA clinical hold at lower doses. Credit Suisse said it is defending Esperion shares on the pullback and reiterates its Outperform rating and $130 price target on the stock.